Insights into Multiple Myeloma During the COVID-19 pandemic
Report on adjustments to treatment practices for multiple myeloma (MM) patients during the COVID-19 pandemic
July 15, 2020
Faculty Chair
Rafael Fonseca, MD
Washington Mayo Clinic, Phoenix, AZ, US
KEY TAKE AWAYS
- A virtual, moderated roundtable discussion focusing on treatment of MM in the context of the COVID-19 pandemic was held on July 15, 2020
- Disease state and data presentations were developed in conjunction with Dr Rafael Fonseca from Mayo Clinic
- Community oncologists were invited from Arizona, California, Colorado, Florida, Georgia, Michigan, New Jersey, and New York
- Attendees of the roundtable represented community oncologists from Arizona, California, Florida, Georgia, Michigan, New Jersey, and New York
- Insights on the following therapies were obtained: bortezomib, carfilzomib, ixazomib, elotuzumab, daratumumab, lenalidomide, pomalidomide, thalidomide, melphalan, cyclophosphamide, bendamustine, panobinostat, selinexor, isatuximab, and venetoclax
- Data collection was accomplished through use of audience response system questioning and moderated discussion
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Attendees of the roundtable represented community oncologists from Arizona, California, Florida, Georgia, Michigan, New Jersey, and New York
